healthprotocol.wiki
Protocols
Evidence
Outcomes
Home
/
Evidence
mateos-mv_2025_rct_teclistamab-plus-daratumumab-vs-daratumumab-triplets-in-rrmm-majestec-3
2 findings
Protocol
medication-cancer-teclistamab-daratumumab-combined-generic
Outcome
survival-overall-proportion-cohort-measured
n
300
effect
70
attribution
85
Protocol
medication-cancer-teclistamab-daratumumab-combined-generic
Outcome
survival-progression-free-proportion-cohort-measured
n
300
effect
90
attribution
85
healthprotocol.wiki